LAM226 en el tratamiento de neuropatías: Desarrollo preclínico y nuevos candidatos. NEUROPAT226

This project, reference CPP2021-008855, is supported by  MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR.

The project aims to test a number of molecules developed by Laminar Pharma(mainly LAM226) in neurodegenerative diseases such as Parkinson’s disease and in the neuropathic pain derived from nervous injuries. The partners of this project are:

 Completion period: 31 December 2024

 

Supported by:

 

 

Evaluation of antiviral agents against COVID-19 and other viral pathologies

 

 

 

This project has been co-founded by the European Regional Developing Fund (ERDF), Thematic Objective 1, which pretends to promote technological development, innovation and quality research, and Junta de Castilla y León through the Instituto para la Competitividad Empresarial (ICE).

 

This research project is addressed to test molecules against COVID 19 and other viral agents.

 

Grant expedient number: 14/21/LE/0005

 

Completion period: 28 December 2022

 

 

 

Targeted delivery of antiinflammatory microRNAs through exosomes

 

 

 

This project has been granted to Neural Therapies SL by the European Regional Developping Fund (ERDF) from European Union and Junta de Castilla y León through the Instituto para la Competitividad Empresarial (ICE).

 

This research project is developping technology for the design and purification of exosomes. These microvesicles will be loaded with specific microRNAs to explore they potential use as antiinflamatory agents.

 

Grant expedient number: 04/18/LE/0009

 

Completion period: 28 February 2021

 

 

LAM226 en el tratamiento de neuropatías: Desarrollo preclínico y nuevos candidatos. NEUROPAT226

This project, reference CPP2021-008855, is supported by  MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR.

The project aims to test a number of molecules (mainly LAM226) in neurodegenerative diseases such as Parkinson’s disease and in the neuropathic pain derived from nervous injuries. The partners of this project are:

 Completion period: 31 December 2024

 

Supported by:

 

 

Evaluation of antiviral agents against COVID-19 and other viral pathologies

 

 

 

This project has been co-founded by the European Regional Developing Fund (ERDF), Thematic Objective 1, which pretends to promote technological development, innovation and quality research, and Junta de Castilla y León through the Instituto para la Competitividad Empresarial (ICE).

 

This research project is addressed to test molecules against COVID 19 and other viral agents.

 

Grant expedient number: 14/21/LE/0005

 

Completion period: 28 December 2022

 

 

 

Targeted delivery of antiinflammatory microRNAs through exosomes

 

 

 

This project has been granted to Neural Therapies SL by the European Regional Developping Fund (ERDF) from European Union and Junta de Castilla y León through the Instituto para la Competitividad Empresarial (ICE).

 

This research project is developping technology for the design and purification of exosomes. These microvesicles will be loaded with specific microRNAs to explore they potential use as antiinflamatory agents.

 

Grant expedient number: 04/18/LE/0009

 

Completion period: 28 February 2021